Sullivan S J, Schonbrunn A
Laboratory of Toxicology, Harvard School of Public Health, Boston, Massachusetts 02115.
Endocrinology. 1988 Mar;122(3):1137-45. doi: 10.1210/endo-122-3-1137.
Previous studies with heterogeneous populations of pancreatic cells have provided evidence for the presence of somatostatin (SRIF) receptors in cytosol and secretion vesicles, as well as the plasma membrane. To examine the distribution of SRIF receptors between soluble and membrane fractions in a homogeneous pancreatic islet cell population, we have used the clonal RINm5F insulinoma cell line. These cells contain specific, high affinity binding sites for [125I-Try11]SRIF on the cell surface, and occupancy of these sites by SRIF and SRIF analogs correlates with inhibition of insulin secretion. Stable, steady state binding was achieved using both intact cells and membranes by performing binding incubations with [25I-Tyr11]SRIF at 22 C. Half-maximal inhibition of [125I-Tyr11]SRIF binding occurred with 0.21 +/- 0.11 nM SRIF in membranes and 0.35 +/- 0.30 nM SRIF in cells. In contrast, the binding of [125I-Tyr11]SRIF to cytosolic macromolecules was not reduced by concentrations of SRIF as high as 100 nM, demonstrating that this binding was of much lower affinity. RINm5F membranes were further purified using a Percoll gradient to prepare a microsomal fraction, which was enriched in adenylate cyclase activity, and a secretory granule fraction, which was enriched in insulin. [125I-Tyr11]SRIF binding to the microsomal fraction (3.8 +/- 0.3 fmol/mg) was 3 times higher than to secretion granules (1.2 +/- 0.2 fmol/mg). Thus, high affinity SRIF binding sites were most abundant in microsomal membranes and were low or undetectable in secretory granules and cytosol. To determine whether translocation of SRIF receptors to the plasma membrane accompanied insulin secretion, we examined the effects of various insulin secretagogues on [125I-Tyr11]SRIF binding to intact cells. Leucine (20 mM), glyceraldehyde (15 mM), forskolin (1 microM), and glucagon (1 microM) stimulated insulin release 1.5- to 4.0-fold in different experiments. However, these secretagogues did not increase [125I-Tyr11]SRIF binding. In summary, our results indicate that high affinity SRIF receptors in RINm5F cells are located primarily on the plasma membrane and that the concentration of SRIF receptors at the cell surface is independent of the secretory activity of the cells.
先前针对异质性胰腺细胞群体的研究已证实,在细胞溶质、分泌囊泡以及质膜中均存在生长抑素(SRIF)受体。为了研究在均一的胰岛细胞群体中,SRIF受体在可溶性组分和膜组分之间的分布情况,我们使用了克隆的RINm5F胰岛素瘤细胞系。这些细胞在细胞表面含有针对[125I - Try11]SRIF的特异性高亲和力结合位点,并且SRIF和SRIF类似物对这些位点的占据与胰岛素分泌的抑制相关。通过在22℃下用[25I - Tyr11]SRIF进行结合孵育,完整细胞和膜均实现了稳定的稳态结合。在膜中,0.21±0.11 nM的SRIF可使[125I - Tyr11]SRIF结合抑制一半;在细胞中,该浓度为0.35±0.30 nM。相比之下,高达100 nM的SRIF浓度都不会降低[125I - Tyr11]SRIF与细胞溶质大分子的结合,这表明这种结合的亲和力要低得多。使用Percoll梯度进一步纯化RINm5F膜,以制备富含腺苷酸环化酶活性的微粒体组分和富含胰岛素的分泌颗粒组分。[125I - Tyr11]SRIF与微粒体组分的结合(3.8±0.3 fmol/mg)比与分泌颗粒的结合(1.2±0.2 fmol/mg)高3倍。因此,高亲和力的SRIF结合位点在微粒体膜中最为丰富,而在分泌颗粒和细胞溶质中含量较低或无法检测到。为了确定SRIF受体向质膜的转位是否伴随着胰岛素分泌,我们研究了各种胰岛素促分泌剂对[125I - Tyr11]SRIF与完整细胞结合的影响。在不同实验中,亮氨酸(20 mM)、甘油醛(15 mM)、福斯可林(1 μM)和胰高血糖素(1 μM)可使胰岛素释放增加1.5至4.0倍。然而,这些促分泌剂并未增加[125I - Tyr11]SRIF的结合。总之,我们的结果表明,RINm5F细胞中的高亲和力SRIF受体主要位于质膜上,并且细胞表面SRIF受体的浓度与细胞的分泌活性无关。